Effect of daily nebulisation of a mucolytic and bronchodilation agent in intensive care patients in need for mechanical ventilation because of lungfailure
Recruiting
- Conditions
- ung failure Nebulisation Mechanical ventilationBronchodilator (salbutamol)Mucolytic (acetylcysteine)
- Registration Number
- NL-OMON24245
- Lead Sponsor
- Academic Medical Center Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 950
Inclusion Criteria
Age 18 year or older
Expected duration of intubation and ventilation > 24 hour
Written informed consent
Exclusion Criteria
Ventilation before present ICU admission (though short-term ventilation in the emergency room or in the operation room for general anesthesia during surgery is allowed)
Pregnancy
Lung disease for which inhalation therapy and/or oral steroids are used
Diagnoses of: Guillain-Barré syndrome, complete spinal cord lesion or amyotrophic lateral sclerosis, multiple sclerosis and myasthenia gravis
Allergy for acetylcysteine or salbutamol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of ventilator-free days (VFDs), defined as the number of days from day 1 to day 28 after ICU admission and start of mechanical ventilation
- Secondary Outcome Measures
Name Time Method -ICU and hospital length of stay <br>-ICU and hospital mortality<br>-secondary ARDS<br>-ventilator-associated pneumonia <br>-atelectasis <br>-side effects of nebulisation of mucolytics and bronchodilators <br>-related health care costs will be estimated with a cost benefit – and budget impact analysis